CN101897933A - Chinese patent medicament for treating leucoderma - Google Patents
Chinese patent medicament for treating leucoderma Download PDFInfo
- Publication number
- CN101897933A CN101897933A CN2010102329903A CN201010232990A CN101897933A CN 101897933 A CN101897933 A CN 101897933A CN 2010102329903 A CN2010102329903 A CN 2010102329903A CN 201010232990 A CN201010232990 A CN 201010232990A CN 101897933 A CN101897933 A CN 101897933A
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- chinese patent
- medicine
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 3
- 241000190633 Cordyceps Species 0.000 claims description 13
- 241000522620 Scorpio Species 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000005516 engineering process Methods 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 241001446509 Psoralea Species 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 6
- 239000009490 scorpio Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 2
- -1 sublimed preparation Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 20
- 210000004369 blood Anatomy 0.000 abstract description 19
- 210000003734 kidney Anatomy 0.000 abstract description 16
- 210000004185 liver Anatomy 0.000 abstract description 14
- 238000000034 method Methods 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 4
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000036737 immune function Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 3
- 244000241463 Cullen corylifolium Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 241000233866 Fungi Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 235000017784 Mespilus germanica Nutrition 0.000 abstract 1
- 244000182216 Mimusops elengi Species 0.000 abstract 1
- 235000000560 Mimusops elengi Nutrition 0.000 abstract 1
- 240000001307 Myosotis scorpioides Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 235000017276 Salvia Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 241000951473 Schizonepeta Species 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 235000007837 Vangueria infausta Nutrition 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- OARRHUQTFTUEOS-UHFFFAOYSA-N safranin Chemical compound [Cl-].C=12C=C(N)C(C)=CC2=NC2=CC(C)=C(N)C=C2[N+]=1C1=CC=CC=C1 OARRHUQTFTUEOS-UHFFFAOYSA-N 0.000 abstract 1
- 238000010792 warming Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 13
- 206010025421 Macule Diseases 0.000 description 12
- 206010047642 Vitiligo Diseases 0.000 description 11
- 230000007812 deficiency Effects 0.000 description 9
- 239000002994 raw material Substances 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 239000012567 medical material Substances 0.000 description 5
- 208000008035 Back Pain Diseases 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 4
- 208000008930 Low Back Pain Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000036461 convulsion Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000007844 bleaching agent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024380 Leukoderma Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese patent medicament for treating leucoderma. In the traditional Chinese patent medicament, medlar, malaytea scurfpea fruit, safranine, curcuma longa, divaricate saposhnikovia root, root of red-rooted salvia, glossy privet fruit, belvedere fruit, fineleaf schizonepeta herb, Chinese caterpillar fungus, scorpion and tuber fleeceflower root are prepared into various formulations for oral administration by a conventional pharmaceutical method. The Chinese patent medicament has the effects of warming, invigorating liver and kidney, dispelling wind, dehumidifying, coordinating qi and blood, clearing and activating the channels and collaterals, promoting blood circulation, removing blood stasis, regulating the immunologic function and improving skin microcirculation, and has the characteristics of definite curative effect on the treatment and prevention of the leucoderma and convenient administration.
Description
Technical field:
The present invention relates to vitiligo disease treatment technical field, relate in particular to the leukodermic Chinese patent medicine of a kind of treatment.
Background technology:
Vitiligo is a kind of common posteriority, circumscribed depigmentation dermatoses, can betide any age, is more common in child and youth.The sick limitation decolouring speckle that decreases to differing in size, clear-cut margin, on every side with the healthy skin intersection, color of the leather is denseer; Kainogenesis damages common have temporary inflammatory halo, number or single-shot or pilosity on every side, can merge mutually in flakes, and the affected part hair can bleach, and does not have any subjective symptoms, and damaging part has bright gargalesthesia after the Exposure to Sunlight.Primary disease is relevant with the various autoimmune disease, as some patients with vitiligo or its relatives, can be associated with hyperthyroidism and go down, diabetes etc.; The organ specific antibody of finding thyroid, stomach, adrenal tissue in some patient's the blood exists.Primary disease often has family history, has family's genetic predisposition.In addition, with body in copper, zinc ion content lower relevant.The patient is many to increase with perspiration, the performance increase in temperature, and diseases such as bleeding time prolongation, the reason that takes place as the vitiligo disease belongs to blood deficiency and blood stasis wind-engaging person more.
At present, it is a lot of to treat this sick method and medicine, but can not reach ideal effect, Therapeutic Method such as " laser ", " skin-grafting ", " freezing " for example, and not only weak curative effect is returned skin and is stayed scar; Some medicine such as patent medicine: the speckle removing ball, remove Bai Su, white macula tincture etc., these medicines existence take effect slowly, the course of treatment is long, shortcomings such as the low and relapse rate height of cure rate, the medicine that has also has irritated and slight toxic reaction, the medicine that also has easily causes side effect such as liver,kidney,spleen enlargement, brings misery to the patient.
Summary of the invention
Technical problem to be solved by this invention provides a kind of to eliminate patient's illness, and the promotion physical and mental health has the leukodermic Chinese patent medicine of treatment that the patient takes medicine conveniently, curative effect is fast, have no side effect simultaneously.
For solving the problems of the technologies described above, the present invention adopts following technical scheme: the leukodermic Chinese patent medicine of a kind of treatment, its special character is the medicine by the following weight proportioning: Fructus Lycii 30-50 part, Fructus Psoraleae 30-50 part, Stigma Croci 1-2.5 part, Rhizoma Curcumae Longae 30-50 part, Radix Saposhnikoviae 30-50 part, Radix Salviae Miltiorrhizae 30-50 part, Fructus Ligustri Lucidi 30-50 part, Fructus Kochiae 30-50 part, Herba Schizonepetae 30-50 part, Cordyceps 1-2.5 part, Scorpio 10-20 part, Radix Polygoni Multiflori 30-50 part.
The preferred version of the medicine of above-mentioned weight proportion is: Fructus Lycii 35-45 part, Fructus Psoraleae 35-45 part, Stigma Croci 1.5-2 part, Rhizoma Curcumae Longae 35-45 part, Radix Saposhnikoviae 35-45 part, Radix Salviae Miltiorrhizae 35-45 part, Fructus Ligustri Lucidi 35-45 part, Fructus Kochiae 35-45 part, Herba Schizonepetae 35-45 part, Cordyceps 1.5-2 part, Scorpio 12.5-17.5 part, Radix Polygoni Multiflori 35-45 part.
The preferred plan of the medicine of above-mentioned weight proportion is: 40 parts of Fructus Lycii, 40 parts of Fructus Psoraleaes, 1.75 parts of Stigma Crocis, 40 parts in Rhizoma Curcumae Longae, 40 parts of Radix Saposhnikoviaes, 40 parts of Radix Salviae Miltiorrhizaes, 40 parts of Fructus Ligustri Lucidi, 40 parts of the Fructus Kochiae, 40 parts of Herba Schizonepetae, 1.75 parts of Cordyceps, 15 parts of Scorpios, 40 parts of Radix Polygoni Multiflori.
Above-mentioned described Chinese patent medicine is made different oral medicine dosage forms such as pill, sublimed preparation, powder, tablet, unguentum, decoction and capsule dress powder according to the conventional technology of preparing of Chinese medicine, and adds the necessary medicine excipient in different separately dosage forms.
Chinese patent medicine of the present invention has proper, the reasonable recipe of compatibility of drugs, and the effect of its described each herbal medicine is:
Fructus Lycii: sweet in the mouth, property are flat, have the effect of nourishing the liver and kidney, replenishing vital essence to improve eyesight, but tonifying liver blood, kidney tonifying warp, supporting YANG QI, strengthening bone and muscle are usually used in the Liver and kidney essence and blood and lose the various diseases that void causes.
Fructus Psoraleae: acrid in the mouth, warm in nature, nontoxic, effect with enriching yin and nourishing kidney is usually used in that Yuanyang declines that damage, five kinds of strain and seven kinds of impairment, lumbago due to renal deficiency, kidney qi deficiency and coldness, vital essence are solid, the enuresis, spleen suffer from a deficiency of the kidney and rush down, watery diarrhea chronic dysentery, pregnant woman's lumbago, fall and weigh down diseases such as lumbago, blood stasis stagnate;
Stigma Croci: sweet in the mouth, property are put down, and have the effect of blood circulation promoting and blood stasis dispelling, dispersing stagnation and relieving accumulation of pathogens.Be usually used in treating that the chest and diaphragm painful abdominal mass is vexed, haematemesis, typhoid fever are gone mad, frightenedly be afraid of in a trance, women's amenorrhea, diseases such as postnatal blood stasis stomachache, treating swelling and pain by traumatic injury.
Rhizoma Curcumae Longae: have the antipruritic effect of analgesia acrid in the mouth hardship, property Great Cold, nontoxic, be usually used in pained unbearably, fetal cold stomachache, baby crying milk regurgitation, shape such as infantile convulsion, puerperal blood pain, skin ulcer tinea disease such as just;
Radix Saposhnikoviae: acrid in the mouth, sweet, slightly warm in nature, return bladder, liver, spleen channel, have the effect of expelling pathogenic wind from the body surface, removing dampness to relieve pain, relieving convulsion, be used for the treatment of diseases such as diseases caused by exogenous pathogenic factor exterior syndrome, rubella pruritus, rheumatic arthralgia, tetanus.
Radix Salviae Miltiorrhizae: bitter in the mouth, cold nature, the GUIXIN Liver Channel has the effect of blood circulation promoting and blood stasis dispelling, menstruction regulating and pain relieving, removing heat from blood mind calming.
Fructus Ligustri Lucidi: sweet-bitter flavor, cold nature, return the Liver and kidney warp, have nourishing the liver and kidney, the effect that black hair makes eye bright, this product go into Liver and kidney can benefiting essence-blood, black beard and hair, Pingyin fire, reducing the asthenic fever, is usually used in treating deficiency of the liver and kindey and causes disease;
The Fructus Kochiae: sweet-bitter flavor, cold in nature has the effect of clearing away damp-heat, diuresis; Be used for the treatment of diseases such as skin eczema, dribbling urination, beriberi edema.
Herba Schizonepetae: acrid in the mouth, slightly warm in nature, return lung, Liver Channel, have the diffusing wind that induces sweat, rash, the skin ulcer that disappears, hemostatic effect, be usually used in treatment flu, measles send out thoroughly smooth, have blood in stool, diseases such as metrorrhagia, epistaxis.
Cordyceps: sweet in the mouth, flat, warm in nature, return lung, kidney channel, the effect that mainly has invigorating the lung and the kidney, hemostasis and phlegm, be usually used in treating chronic cough dyspnea due to deficiency, the chronic cough expectorant blood of lumbago due to renal deficiency, impotence and seminal emission, deficiency of both the lung and kidney, regulate body's immunity, suppress diseases such as lupus erythematosus, blood sugar lowering, antitumor.
Scorpio: acrid in the mouth, property are flat, poisonous, have relieve dizziness, high fever, infantile convulsions, epilepsy, etc., spasmolytic, analgesic effect.Be used for the treatment of diseases such as convulsion with spasms, headache, rheumatalgia.
Radix Polygoni Multiflori: sweetness and bitterness, puckery, slightly warm in nature is returned liver, kidney channel, has nourishing the blood and yin, loosening bowel to relieve constipation, preventing the attack (or recurrence) of malaria, dispels the wind, the antidotal effect.Cure mainly a little less than the waist knee joint acid of blood deficiency Light-headedness, cardiopalmus, insomnia, the hepatic and renal YIN deficiency; Early whitening of beard and hair, tinnitus, seminal emission, dryness of the intestine constipation; Chronic malaria body void; Diseases such as rubella pruritus, carbuncle sore, scrofula, hemorrhoid.
The present invention follows the principles of formulating prescriptions of the traditional Chinese medical science " monarch ", and all composition comes from the 5th edition medicine that records of China's " pharmacopeia ", and all medicines have the temperature compensation Liver and kidney mutually and altogether, the wind that looses dehumidifies, QI and blood regulating, is set upright and is got rid of evils dredge the meridian passage, blood circulation promoting and blood stasis dispelling, regulates immunologic function, improve skin microcirculation, promote skin pigment to generate, the effect of the white and moist skin that disappears, treatment and prevention vitiligo, determined curative effect, have no side effect various Chinese medicine preparation taking conveniences.
Clinical drug of the present invention uses the result to show to have following advantage:
1, the Chinese medicine each component selected for use of the present invention meets the regulation of The Drug Administration Law of People's Republic of China, utilizes the comprehensive function treatment and the prevention vitiligo of the Chinese medicine of respectively distinguishing the flavor of, and is nontoxic to human body.Acute toxicity test and accumulation toxicity test through white mice and rat show that underproof animal does not see any toxic reaction, compare zero difference through anatomic observation hemogram, liver function, each organs and tissues morphology finding and matched group, prove that its safety of medicine is reliable.
2, Chinese medicine preparation of the present invention need not decoct, not have bitterness sense, rich in proteins, glucose, glucuronic acid, volatile oil, pectin, fructose, organic acid, lecithin, vitamin, aminoacid in the medicine, also contain various trace elements such as Saponin, plant sterol, calcium, help absorption of human body, health invigorating, and taking convenience.
3, Chinese medicine preparation of the present invention not only can effectively be treated vitiligo, and it is also very obvious to leukodermic preventive effect, particularly by working in coordination with mutually between the medicine, strengthen medicine and treat characteristic separately, by dredge the meridian passage and adjusting immunologic function, improve the intrinsic healthy energy of patient body and physical and mental health and life quality, reached the healing rehabilitation efficacy preferably.
Further specify medicine of the present invention to treatment therapy for vitiligo effect below by the clinical practice example.
One, clinical diagnosis standard:
Leukodermic clinical manifestation is: the skin of any department of whole body all can take place, but originates from easy solar radiation and damage by friction portion, also can involve as the inboard mucosa of facial area, cervical region, trunk and extremity, lip, labia, glans penis and foreskin.Most of leukasmus is symmetrically distributed, and also has part patient white macula to distribute along nerve segment.Skin lesion is locality depigmentation speckle, milky, from fingernail to the coin size, circular, oval or irregular shape.White macula place hair also can bleach.In progressive stage, the decolouring speckle is divided a word with a hyphen at the end of a line to normal skin, and development is very fast, and isomorphic response is arranged, and promptly can form the secondary vitiligo after pressure, friction, the wound.
Can divide three types according to leukoderma scope and distribution:
1, limitation: skin lesion is confined to a position, can be divided into again: (1) segmental pattern: skin lesion is pressed dermatomere and is distributed; (2) mucosal pattern: only involve mucosa.
2, general hair style: the most common, show as skin lesion and be distributed widely in body surface, can be divided into:
(1) homeliness type: skin lesion is dispersed in and is distributed in the body surface many places;
(2) face acra type: skin lesion is distributed in face and far-end of limb;
(3) mixed type: above-mentioned several various combinations form, as face acra type+segmental pattern etc.
3, whole body type: whole skin all decolours fully or almost, also has hair to bleach.
Two, case selection
Leukodermic sickness rate is with area, the ethnic group colour of skin and different, and the dark more people's sickness rate of general colour is high more.Prevalence is about 0.1-2% in the population of China, and M-F can be fallen ill until old every year from the newborn baby about equally, but is many with teenager.Put down in writing according to interrelated data: age of onset is in the majority in 10-30 year, accounts for 62.65% of sum, and women's age of onset was than male about 5 years ahead of time.For this reason, case selection is whole cases with door rash prescription on individual diagnosis patient.
Three, curative effect determinate standard
Before the curative effect determinate standard that not have at present the promulgation of formal country, the vitiligo curative effect determinate standard that the present invention adopts (the scientific and technological publishing house of Chen Qin chief editor " research and development of Chinese medicine cosmetic health product " Chinese Medicine 1999 version the 228th page) is:
(1) recovery from illness: the white macula complete obiteration, histopathology of skin checks normal;
(2) produce effects: white macula disappears more than 50%, and white macula disappearance portion of tissue pathological examination is normal;
(3) effective: white macula disappearance person accounts for the 20-50% of former white macula area, or sees have than the polychrom island in white macula;
(4) invalid: no change or white macula enlarge before and after the treatment.
Four, clinical application method and therapeutic outcome
1, clinical application method
According to patient's sick time, the cause of disease and white macula scope and distribution situation, the component medication:
Take the capsule of embodiment 3, each 3-7 gram, every day 2-3 time, warm water delivery service, take half an hour ante cibum.Two months is a course of treatment, take continuously three the course of treatment observe the curative effect.
2, therapeutic outcome
Amount to 89 examples through clinical diagnosis treatment patients with vitiligo, male's 36 examples, women's 53 examples, the age is 12-50 year.Recovery from illness 58 examples account for 65.2% among the 89 routine patients, and produce effects 23 examples account for 25.8%, and effective 6 examples account for 7%, and invalid 2 examples account for 2%, and total effective rate reaches 98%.After treatment, the patient skin white macula disappears in various degree or fully recover, and patient do not have any untoward reaction, three big routine tests and hepatic and renal function detection do not find any unusually.Fully recover through the patient and to pay a return visit statistics, do not see an example recurrence so far.
The specific embodiment
Embodiment 1
Press the row weight portion and take by weighing each Chinese crude drug:
30 parts in 1 portion of Rhizoma Curcumae Longae of 30 parts of Stigma Crocis of 30 parts of Fructus Psoraleaes of Fructus Lycii
30 parts of 30 parts of Fructus Kochiae of 30 parts of Fructus Ligustri Lucidi of 30 parts of Radix Salviae Miltiorrhizaes of Radix Saposhnikoviae
30 parts of 10 parts of Radix Polygoni Multiflori of 1 portion of Scorpio of 30 parts of Cordyceps of Herba Schizonepetae
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made sublimed preparation according to the pharmaceutical methods that routine prepares sublimed preparation.
Embodiment 2
Press the row weight portion and take by weighing each medical material:
50 parts in 2.5 portions of Rhizoma Curcumae Longaes of 50 parts of Stigma Crocis of 50 parts of Fructus Psoraleaes of Fructus Lycii
50 parts of 50 parts of Fructus Kochiae of 50 parts of Fructus Ligustri Lucidi of 50 parts of Radix Salviae Miltiorrhizaes of Radix Saposhnikoviae
50 parts of 20 parts of Radix Polygoni Multiflori of 2.5 portions of Scorpios of 50 parts of Cordyceps of Herba Schizonepetae
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made packed powder according to the pharmaceutical methods that routine prepares powder.
Embodiment 3
Press the row weight portion and take by weighing each medical material:
35 parts in 1.5 portions of Rhizoma Curcumae Longaes of 35 parts of Stigma Crocis of 35 parts of Fructus Psoraleaes of Fructus Lycii
35 parts of 35 parts of Fructus Kochiae of 35 parts of Fructus Ligustri Lucidi of 35 parts of Radix Salviae Miltiorrhizaes of Radix Saposhnikoviae
35 parts of 12.5 parts of Radix Polygoni Multiflori of 2.5 portions of Scorpios of 35 parts of Cordyceps of Herba Schizonepetae
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made capsule according to the pharmaceutical methods that routine prepares capsule.
Embodiment 4
Press the row weight portion and take by weighing each medical material:
45 parts in 2 portions of Rhizoma Curcumae Longaes of 45 parts of Stigma Crocis of 45 parts of Fructus Psoraleaes of Fructus Lycii
45 parts of 45 parts of Fructus Kochiae of 45 parts of Fructus Ligustri Lucidi of 45 parts of Radix Salviae Miltiorrhizaes of Radix Saposhnikoviae
45 parts of 17.5 parts of Radix Polygoni Multiflori of 2 portions of Scorpios of 45 parts of Cordyceps of Herba Schizonepetae
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made tablet according to the pharmaceutical methods that routine prepares tablet, (as conventional tablet, sugar coated tablet, film coated tablet etc.), and give conventional drug excipient (as starch, sucrose, lactose, calcium stearate, magnesium stearate etc.).
Embodiment 5
Press the row weight portion and take by weighing each medical material:
40 parts in 1.75 portions of Rhizoma Curcumae Longaes of 40 parts of Stigma Crocis of 40 parts of Fructus Psoraleaes of Fructus Lycii
40 parts of 40 parts of Fructus Kochiae of 40 parts of Fructus Ligustri Lucidi of 40 parts of Radix Salviae Miltiorrhizaes of Radix Saposhnikoviae
40 parts of 15 parts of Radix Polygoni Multiflori of 1.75 portions of Scorpios of 40 parts of Cordyceps of Herba Schizonepetae
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made pill according to the pharmaceutical methods that routine prepares pill, and give conventional drug excipient.
Embodiment 6
Press the row weight portion and take by weighing each medical material:
50 parts in 2.2 portions of Rhizoma Curcumae Longaes of 50 parts of Stigma Crocis of 50 parts of Fructus Psoraleaes of Fructus Lycii
45 parts of 45 parts of Fructus Kochiae of 45 parts of Fructus Ligustri Lucidi of 50 parts of Radix Salviae Miltiorrhizaes of Radix Saposhnikoviae
30 parts of 12 parts of Radix Polygoni Multiflori of 2.2 portions of Scorpios of 30 parts of Cordyceps of Herba Schizonepetae
The preparation technology of present embodiment is: above-mentioned each medicinal raw material is made granule according to the pharmaceutical methods that routine prepares granule.
Claims (5)
1. treat leukodermic Chinese patent medicine for one kind, it is characterized in that medicine: Fructus Lycii 30-50 part, Fructus Psoraleae 30-50 part, Stigma Croci 1-2.5 part, Rhizoma Curcumae Longae 30-50 part, Radix Saposhnikoviae 30-50 part, Radix Salviae Miltiorrhizae 30-50 part, Fructus Ligustri Lucidi 30-50 part, Fructus Kochiae 30-50 part, Herba Schizonepetae 30-50 part, Cordyceps 1-2.5 part, Scorpio 10-20 part, Radix Polygoni Multiflori 30-50 part by the following weight proportioning.
2. the leukodermic Chinese patent medicine of treatment according to claim 1 is characterized in that the medicine by the following weight proportioning; Fructus Lycii 35-45 part, Fructus Psoraleae 35-45 part, Stigma Croci 1.5-2 part, Rhizoma Curcumae Longae 35-45 part, Radix Saposhnikoviae 35-45 part, Radix Salviae Miltiorrhizae 35-45 part, Fructus Ligustri Lucidi 35-45 part, Fructus Kochiae 35-45 part, Herba Schizonepetae 35-45 part, Cordyceps 1.5-2 part, Scorpio 12.5-17.5 part, Radix Polygoni Multiflori 35-45 part.
3. the leukodermic Chinese patent medicine of treatment according to claim 1 is characterized in that the medicine by the following weight proportioning: 40 parts of Fructus Lycii, 40 parts of Fructus Psoraleaes, 1.75 parts of Stigma Crocis, 40 parts in Rhizoma Curcumae Longae, 40 parts of Radix Saposhnikoviaes, 40 parts of Radix Salviae Miltiorrhizaes, 40 parts of Fructus Ligustri Lucidi, 40 parts of the Fructus Kochiae, 40 parts of Herba Schizonepetae, 1.75 parts of Cordyceps, 15 parts of Scorpios, 40 parts of Radix Polygoni Multiflori.
4. according to the leukodermic Chinese patent medicine of the described treatment of arbitrary claim in the claim 1 to 3, it is characterized in that described Chinese patent medicine makes different oral medicine dosage forms such as pill, sublimed preparation, powder, tablet, unguentum, decoction and capsule dress powder according to the conventional technology of preparing of Chinese medicine.
5. the leukodermic Chinese patent medicine of treatment according to claim 4 is characterized in that described Chinese patent medicine also contains drug excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102329903A CN101897933B (en) | 2010-07-18 | 2010-07-18 | Chinese patent medicament for treating leucoderma |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102329903A CN101897933B (en) | 2010-07-18 | 2010-07-18 | Chinese patent medicament for treating leucoderma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101897933A true CN101897933A (en) | 2010-12-01 |
| CN101897933B CN101897933B (en) | 2012-07-04 |
Family
ID=43224074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102329903A Expired - Fee Related CN101897933B (en) | 2010-07-18 | 2010-07-18 | Chinese patent medicament for treating leucoderma |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101897933B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058795A (en) * | 2010-12-08 | 2011-05-18 | 古秀根 | External lotion for treating vitligo |
| CN102430097A (en) * | 2011-11-29 | 2012-05-02 | 渠淑敏 | Chinese medicine for treating vitiligo |
| CN103251847A (en) * | 2013-06-05 | 2013-08-21 | 高忠青 | Traditional Chinese medicine for treating leucoderma |
| CN104547874A (en) * | 2013-10-15 | 2015-04-29 | 陈迎春 | Traditional Chinese medicine preparation for treating vitiligo |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103587A (en) * | 1993-12-10 | 1995-06-14 | 张祖球 | Pills for leukodermia |
| CN1318379A (en) * | 2000-04-20 | 2001-10-24 | 陈江辉 | Leukoderma treating ointment and its preparation |
| CN101234162A (en) * | 2007-12-21 | 2008-08-06 | 汤铁强 | Chinese medicine formula for treating leukoderma and preparation thereof |
-
2010
- 2010-07-18 CN CN2010102329903A patent/CN101897933B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1103587A (en) * | 1993-12-10 | 1995-06-14 | 张祖球 | Pills for leukodermia |
| CN1318379A (en) * | 2000-04-20 | 2001-10-24 | 陈江辉 | Leukoderma treating ointment and its preparation |
| CN101234162A (en) * | 2007-12-21 | 2008-08-06 | 汤铁强 | Chinese medicine formula for treating leukoderma and preparation thereof |
Non-Patent Citations (2)
| Title |
|---|
| 《中国中医药信息杂志》 20060131 李广瑞等 白癜风辨治三则 81 1-5 第13卷, 第1期 2 * |
| 《甘肃中医》 20081231 查日煌 中医药治疗白癜风的新进展 57-61 1-5 第21卷, 第3期 2 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102058795A (en) * | 2010-12-08 | 2011-05-18 | 古秀根 | External lotion for treating vitligo |
| CN102430097A (en) * | 2011-11-29 | 2012-05-02 | 渠淑敏 | Chinese medicine for treating vitiligo |
| CN103251847A (en) * | 2013-06-05 | 2013-08-21 | 高忠青 | Traditional Chinese medicine for treating leucoderma |
| CN103251847B (en) * | 2013-06-05 | 2014-10-22 | 河北工程大学 | Traditional Chinese medicine for treating leucoderma |
| CN104547874A (en) * | 2013-10-15 | 2015-04-29 | 陈迎春 | Traditional Chinese medicine preparation for treating vitiligo |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101897933B (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102416079A (en) | Chinese patent medicine for treating leucoderma | |
| CN102362950A (en) | Traditional Chinese medicine for treating leucoderma | |
| CN101897933B (en) | Chinese patent medicament for treating leucoderma | |
| CN102727648A (en) | Chinese medicinal composition for treating vitiligo | |
| CN102430097A (en) | Chinese medicine for treating vitiligo | |
| CN102430013A (en) | Chinese medicine for treating vitiligo | |
| CN104784538B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of diabetes | |
| CN110339276A (en) | Traditional Chinese medicine for treating digestive tract tumor and preparation method thereof | |
| CN102423433A (en) | Traditional Chinese drug mixture for treating psoriasis | |
| CN102406866A (en) | Chinese medicinal composition for treating psoriasis | |
| CN102579975B (en) | Traditional Chinese medicine mixture for treating psoriasis | |
| CN100431578C (en) | Preparation of Chinese traditional medicine for treating hyperplasia of prostate | |
| CN100415288C (en) | A Chinese traditional medicinal preparation for treatment of psoriasis | |
| CN102406893A (en) | Chinese patent medicine for treating psoriasis. | |
| CN102406865A (en) | Chinese medicinal composition for treating psoriasis | |
| CN105125911A (en) | Traditional Chinese medicinal composition for regulating and treating benign prostatic hyperplasia and preparation method of traditional Chinese medicinal composition | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN102423458A (en) | Chinese patent medicine for treating psoriasis | |
| CN102552824B (en) | Traditional Chinese medicine prepared prescription for treating psoriasis | |
| CN102362957B (en) | Chinese prepared medicine for treating deep lupus erythematosus | |
| CN102641422B (en) | Chinese patent medicine for treating acute urticaria | |
| CN102416099A (en) | Traditional Chinese medicine for treating psoriasis | |
| CN101019988B (en) | Diabetes treating Chinese medicine | |
| CN101095749A (en) | Chinese patent drug for treating diabetic constipation | |
| CN100546607C (en) | The leukodermic Chinese medicine preparation of a kind of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Chen Fuzheng Document name: Notification to Go Through Formalities of Registration |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: A. V. T. (LIYANG) MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: CHEN FUZHENG Effective date: 20131210 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 264000 YANTAI, SHANDONG PROVINCE TO: 213300 CHANGZHOU, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20131210 Address after: 213300, 168, Shen Shen road, Liyang, Jiangsu, Changzhou Patentee after: A.V.T.(Liyang) Medical Science & Technology Co., Ltd. Address before: 264000 No. 11, Wenhua Road, Zhifu District, Shandong, Yantai Patentee before: Chen Fuzheng |
|
| ASS | Succession or assignment of patent right |
Owner name: RUDONG XINDIAN FARMLAND IRRIGATION AND DRAINAGE SE Free format text: FORMER OWNER: A. V. T. (LIYANG) MEDICAL TECHNOLOGY CO., LTD. Effective date: 20141225 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 213300 CHANGZHOU, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141225 Address after: 226400 Jiangsu Nantong County, Rudong province new town neighborhood committee Patentee after: Rudong Xin County farm irrigation and drainage Service Co., Ltd. Address before: 213300, 168, Shen Shen road, Liyang, Jiangsu, Changzhou Patentee before: A.V.T.(Liyang) Medical Science & Technology Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 Termination date: 20160718 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |